Chinese Journal of Tissue Engineering Research ›› 2011, Vol. 15 ›› Issue (5): 810-812.doi: 10.3969/j.issn.1673-8225.2011.05.012

Previous Articles     Next Articles

Conversion treatment using sirolimus for kidney transplant recipients

Xu Zhi-qiang1, Wan You-gui1, Chen Bo1, Xu Wen-ying1, Feng Yu-hong1, Zhou Hong-lan2   

  1. 1Tongliao Municipal Hospital, Tongliao  028200, Inner Mongolia Autonomous Region, China
    2First Hospital of Jilin University, Changchun  130021, Jilin Province, China
  • Received:2010-08-04 Revised:2010-10-28 Online:2011-01-29 Published:2011-01-29
  • Contact: Zhou Hong-lan, Doctor, Chief physician, First Hospital of Jilin University, Changchun 130021, Jilin Province, China
  • About author:Xu Zhi-qiang★, Master, Attending physician, Tongliao Municipal Hospital, Tongliao 028200, Inner Mongolia Autonomous Region, China chenmuxin@126.com

PDF

420

Abstract:

BACKGROUND: Traditional calcium the phosphoric acid enzymes inhibitors can result in a chronic renal transplants kidney disease. Vaccination sirolimus inhibitors provide new substitution for the treatment.
OBJECTIVE: To verify the efficacy and safety of conversion treatment of sirolimus for kidney transplant recipients.
METHODS: Sixty eligible kidney transplant recipients treated with calcineurin inhibitor as main immunosuppressives were converted to sirolimus. The clinical outcome, complications and side effects were observed.
RESULTS AND CONCLUSION: Eight recipients (13.3%) experienced acute rejection. The renal functions of recipients with chronic renal transplants kidney disease were improved after conversion treatment. The liver damage or hyperglycemia also improved in other recipients. The results demonstrated that sirolimus is superior to calcineurin inhibitor in conversion treatment.

CLC Number: